Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Will The New Focus On Treating Obesity Make A Difference? A Primary Research Case Study | 6461
Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Increasing focus on the rising incidence of obesity in the US is changing the landscape for obesity treatment. Two
new weight loss drugs were approved in June and July 2012 by the FDA, making them the first new weight loss drugs approved in
this country in more than a decade. And new treatment guidelines issued in June 2012 by the U.S. Preventive Services Task Force
recommend that obese adults be offered at least 12 weeks of intensive counseling about lifestyle changes, though use of weight loss
medications was not endorsed by the task force because members couldn?t find evidence to support effectiveness. How will new
treatment options and guidelines affect physicians and payors? How will regulators balance the risks of new drugs versus obesity
as a major public health concern? As an MD with clinical experience, a researcher trained at the Harvard School of Public Health,
and a former Associate Partner at McKinsey & Company in their healthcare practice, Richa Pande will address these questions by
sharing the results of in depth quantitative and qualitative GLG research conducted among key stakeholders including:
new medications, and the role they feel that patients can and should play in weight loss.
and Medicaid uncover intentions regarding payment for behavioral therapies, key influencers of willingness to pay, and
the FDA?s view of drug safety and efficacy vs. the need to fight fat
The data and interviews with experts Dr. Pande will share will reveal how obesity treatment is changing and the likely impact
of recent scientific advances and policy decisions on future health outcomes. Insights from these stakeholders are valuable to
pharmaceutical and biotech executives considering entering this therapeutic area, which is currently penetrated at only 1.2% and
estimated to be worth$1.8 billion in U.S. sales by 2018.
Attendees will learn:
A general understanding of the severity and ramifications of the U.S.?s growing rate of obesity
The attitudes and actions that key stakeholders are taking in response to the crisis
How those responses are likely to play out in the near future via research with key stakeholders
How this same approach can be applied cost effectively to a wide range of new disease treatment solutions.
Richa Pande is Senior Vice President, Life Sciences at Gerson Lehrman Group (GLG). Richa directs how the firm serves the world's leading
pharmaceutical, biotechnology and medical device firms, and oversees the rapid expansion of GLG into these new markets and industry
subspecialties. The Life Sciences division helps industry executives make better decisions and move better drugs and devices to market sooner and
more efficiently. Clients use GLG to connect with outside experts and academics to test hypotheses, prepare to address changes in the external
environment, make better resource allocations and help prioritize and manage investments in new markets. Richa was most recently Associate
Partner at McKinsey & Company where she spent six years counseling C-level and senior-level executives at major healthcare companies,
investment and public sector organizations on their most critical decisions and issues. Her healthcare and pharmaceutical expertise includes
corporate strategy, business development, M&A, emerging markets, go-to-market strategies, organizational effectiveness and regulatory issues.
She is passionate about innovation in healthcare and better decision making to improve quality, access and sustainability. Richa was a post-doctoral
fellow in Health Care Management at Harvard University Health Services, a research associate for the Harvard School of Public Health and a
medical officer at two major hospitals in India. She holds a Master of Public Health degree from the Harvard School of Public Health and an MBBS
(equivalent to an MD degree) from Bangalore Medical College.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals